QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.053413v1 306/3/1058    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Charrois, G. J. R. Articles by Allen, T. M. Search for Related Content PubMed PubMed Citation Articles by Charrois, G. J. R. Articles by Allen, T. M.

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Multiple Injections of Pegylated Liposomal Doxorubicin: Pharmacokinetics and Therapeutic Activity

Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada

Effects of multiple injections of liposomal doxorubicin on pharmacokinetics, therapeutic outcome, and toxicity were studied in mice using different dosing schedules and dose intensities. Biodistribution of doxorubicin to the cutaneous tissues of mice (skin and paws) and to orthotopically implanted mammary tumors (4T1) was examined. Weekly intravenous administration of pegylated (STEALTH) liposomal doxorubicin (SL-DXR) at a dose of 9 mg/kg (every week x 4 doses) resulted in accumulation of doxorubicin in cutaneous tissues of mice and development of lesions resembling palmar-plantar erythrodysesthesia (PPE). Lengthening the dose interval to every 2 weeks x 4 doses reduced the accumulation of doxorubicin and lowered the incidence of PPE-like lesions. A dose interval of every 4 weeks x 4 resulted in complete clearance of doxorubicin from tissues between subsequent doses and a negligible incidence of PPE-like lesions. Doses of 9 mg/kg SL-DXR given at every week x 2 or every 2 weeks x 2 had similar therapeutic activities, whereas prolonging the dose interval to every 4 weeks x 2 reduced therapeutic activity. Pharmacokinetics, biodistribution, and therapeutic activity were studied in tumor-bearing mice for three dose schedules having the same dose intensity (4.5 mg/kg every 3 days x 4, 9 mg/kg every week x 2, or 18 mg/kg every 2 weeks x 1). For these schedules, larger doses administered less often tended to be superior therapeutically to smaller doses given more often. These data provide the first pharmacokinetic measurements of doxorubicin concentrations in cutaneous tissues and tumors with repeat administration of liposomal formulations, and they provide a useful model for the study of factors leading to PPE in humans.

Address correspondence to: Theresa M. Allen, Department of Pharmacology, University of Alberta, -31 Medical Sciences Building, Edmonton, AB Canada T6G 2H7. E-mail: terry.allen{at}ualberta.ca

This article has been cited by other articles:

				A. MARTSCHICK, J. SEHOULI, A. PATZELT, H. RICHTER, U. JACOBI, G. OSKAY-OZCELIK, W. STERRY, and J. LADEMANN The Pathogenetic Mechanism of Anthracycline-induced Palmar-plantar Erythrodysesthesia Anticancer Res, June 1, 2009; 29(6): 2307 - 2313. [Abstract] [Full Text] [PDF]

				T. A. ElBayoumi and V. P. Torchilin Tumor-Targeted Nanomedicines: Enhanced Antitumor Efficacy In vivo of Doxorubicin-Loaded, Long-Circulating Liposomes Modified with Cancer-Specific Monoclonal Antibody Clin. Cancer Res., March 15, 2009; 15(6): 1973 - 1980. [Abstract] [Full Text] [PDF]

				D Lorusso, A Di Stefano, V Carone, A Fagotti, S Pisconti, and G Scambia Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome) Ann. Onc., July 1, 2007; 18(7): 1159 - 1164. [Abstract] [Full Text] [PDF]

				R. D. Arnold, D. E. Mager, J. E. Slack, and R. M. Straubinger Effect of Repetitive Administration of Doxorubicin-Containing Liposomes on Plasma Pharmacokinetics and Drug Biodistribution in a Rat Brain Tumor Model Clin. Cancer Res., December 15, 2005; 11(24): 8856 - 8865. [Abstract] [Full Text] [PDF]

				H. Sakai, Y. Masada, H. Horinouchi, E. Ikeda, K. Sou, S. Takeoka, M. Suematsu, M. Takaori, K. Kobayashi, and E. Tsuchida Physiological Capacity of the Reticuloendothelial System for the Degradation of Hemoglobin Vesicles (Artificial Oxygen Carriers) after Massive Intravenous Doses by Daily Repeated Infusions for 14 Days J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 874 - 884. [Abstract] [Full Text] [PDF]